Correlation analysis of Poor Prognosis and Immunotherapy of lncRNAs Related with m6A Modification in Cervical Cancer

GU Rui, LIU Min, LIN Ping, FENG Tian-yu, YUAN Hang, OU De-qiong, LI Si-qi, LI Qin, ZHAO Gang, ZHANG Jie,

Abstract

To study the correlation between N6-methyladenosine (m6A)-modification-associated long non-coding RNAs (lncRNAs) and poor prognosis and immunotherapy in cervical cancer based on data mining of The Cancer Genome Atlas (TCGA) cervical cancer dataset, so as to assess effectively the prognosis of cervical cancer patients and the feasibility of immunotherapy.   Methods   We identified m6A-modification-associated lncRNAs correlated to the prognosis of cervical cancer by conducting bioinformatics analysis of cervical cancer samples from the TCGA datasets and constructed a prognostic risk model of cervical cancer accordingly.   Results  A total of 343 m6A-modification-associated lncRNAs were identified from the samples of 304 cervical cancer patients. Univariate Cox regression analysis showed that 26 out of the 343 m6A-modification-associated lncRNAs were significantly associated with the prognosis of cervical cancer patients. We identified 7 m6A-modification-associated lncRNAs, including DLEU1, AC099850.4, DDN-AS1, EP300-AS1, AC131159.1, AL441992.2, and AL021707.6 through Lasso regression analysis and then developed a prognostic risk model based on them. According to the Kaplan-Meier survival analysis, cervical cancer patients in the low-risk group exhibited significantly improved overall survival (OS) in comparison with those in the high-risk group (P<0.001). The area under the curve (AUC) of receiver operating characteristic (ROC) curve analysis demonstrated the high sensitivity and credibility of the risk model. Multivariate Cox analysis showed that the risk score was an independent prognostic factor of cervical cancer patients. Tumor immune dysfunction and exclusion (TIDE) analysis predicted that the high-risk group would benefit more from immunotherapy. In addition, we found that immune checkpoint PD1 was associated with the expression of m6A-modification-related lncRNAs such as DDN-AS1, and the expression was higher in the high-risk group (P<0.05).   Conclusion   The prognostic risk model constructed on the basis of the aforementioned 7 m6A-modification-associated lncRNAs can be used to effectively predict the prognosis of cervical cancer patients and assess the efficacy of immunotherapy targeting PD1.

 

Keywords: Cervical cancer, m6A methylation, lncRNA, Prognosis, Immunotherapy

 

Full Text:

PDF


References


ARBYN M， WEIDERPASS E， BRUNI L， et al. Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. Lancet Glob Health， 2020， 8 (2): e191-e203[2022-01-14]. https://doi.org/10. 1016/S2214-109X(19)30482-6.

LIONTOS M， KYRIAZOGLOU A， DIMITRIADIS I， et al. Systemic therapy in cervical cancer: 30 years in review. Crit Rev Oncol Hematol， 2019，137: 9–17.

JOHNSON C A， JAMES D， MARZAN A， et al. Cervical cancer: An overview of pathophysiology and management. Semin Oncol Nurs，2019， 35(2): 166–174.

BILLAN S， KAIDAR-PERSON O， GIL Z. Treatment after progression in the era of immunotherapy. Lancet Oncol， 2020， 21 (10): e463−e476 [2022-01-14]. https://doi.org/10.1016/S1470-2045(20)30328-4.

WEI G H， WANG X. lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway. Eur Rev Med Pharmacol Sci， 2017，21(17): 3850–3856.

REN J， DING L， ZHANG D， et al. Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19. Theranostics，2018，8(14): 3932–3948.

DAI D， WANG H， ZHU L， et al. N6-methyladenosine links RNA metabolism to cancer progression. Cell Death Dis，2018，9(2): 124.

ZHANG H， SHI X， HUANG T， et al. Dynamic landscape and evolution of m6A methylation in human. Nucleic Acids Res，2020，48(11): 6251–6264.

PARK J W， HAN J W. Targeting epigenetics for cancer therapy. Arch Pharm Res，2019，42(2): 159–170.

TU Z， WU L， WANG P， et al. N6-methylandenosine-related lncRNAs are potential biomarkers for predicting the overall survival of lower-grade glioma patients. Front Cell Dev Biol， 2020， 8: 642[2022-01-14]. https://doi.org/10.3389/fcell.2020.00642.

MA S， CHEN C， JI X， et al. The interplay between m6A RNA methylation and noncoding RNA in cancer. J Hematol Oncol，2019， 12(1): 121.

WANG Y， LU J H， WU Q N， et al. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Mol Cancer， 2019，18(1): 174.

WANG Q， GUO X， LI L， et al. N(6)-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modification. Cell Death Dis，2020，11(10): 911.

KAGABU M， NAGASAWA T， SATO C， et al. Immunotherapy for uterine cervical cancer using checkpoint inhibitors: Future directions. Int J Mol Sci，2020，21(7): 2335.

ZHANG Y， ZHANG Z. The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol， 2020，17(8): 807–821.

PAN J X. LncRNA H19 promotes atherosclerosis by regulating MAPK and NF-kB signaling pathway. Eur Rev Med Pharmacol Sci，2017，21(2): 322–328.

HUANG Y， ZHANG J， HOU L， et al. LncRNA AK023391 promotes tumorigenesis and invasion of gastric cancer through activation of the PI3K/Akt signaling pathway. J Exp Clin Cancer Res，2017，36(1): 194.

WAN Y， YANG Z Q. LncRNA NEAT1 affects inflammatory response by targeting miR-129-5p and regulating Notch signaling pathway in epilepsy. Cell Cycle，2020，19(4): 419–431.

PENG W X， KOIRALA P， MO Y Y. LncRNA-mediated regulation of cell signaling in cancer. Oncogene，2017，36(41): 5661–5667.

SUN J， ZHANG Z， BAO S， et al. Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer. J Immunother Cancer， 2020， 8 (1): e000110[2022-01-14]. https://www. ncbi.nlm.nih.gov/pmc/articles/PMC7057423/. doi: 10.1136/jitc-2019-000110.

XUE L， WU P， ZHAO X， et al. Using immune-related lncRNA signature for prognosis and response to immunotherapy in cutaneous melanoma. Int J Gen Med，2021，14: 6463–6475.

TANG R， ZHANG Y， LIANG C， et al. The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma. PeerJ， 2020， 8: e9602[2022-01-14]. https://peerj.com/articles/9602/. doi: 10.7717/peerj.9602.

DING H， ZHANG L， ZHANG C， et al. Screening of significant biomarkers related to prognosis of cervical cancer and functional study based on lncRNA-associated ceRNA regulatory network. Comb Chem High Throughput Screen，2021，24(3): 472–482.

CHEN Q， HU L， HUANG D， et al. Six-lncRNA immune prognostic signature for cervical cancer. Front Genet， 2020， 11: 533628[2022-01-14]. https://doi.org/10.3389/fgene.2020.533628.

XU Y， LUO H， HU Q， et al. Identification of potential driver genes based on multi-genomic data in cervical cancer. Front Genet， 2021， 12: 598304[2022-01-14]. https://doi.org/10.3389/fgene.2021.598304.

LIU Z， WU M， SHI H， et al. DDN-AS1-miR-15a/16-TCF3 feedback loop regulates tumor progression in cervical cancer. J Cell Biochem， 2019，120(6): 10228–10238.

JIANG N， ZHANG X， HE Y， et al. Identification of key protein-coding genes and lncRNAs in spontaneous neutrophil apoptosis. Sci Rep，2019， 9(1): 15106.

AALIJAHAN H， GHORBIAN S. Long non-coding RNAs and cervical cancer. Exp Mol Pathol，2019，106: 7–16.

ZENG J， MA Y X， LIU Z H， et al. LncRNA SNHG7 contributes to cell proliferation, invasion and prognosis of cervical cancer. Eur Rev Med Pharmacol Sci，2019，23(21): 9277–9285.

ZHANG G， FAN E， ZHONG Q， et al. Identification and potential mechanisms of a 4-lncRNA signature that predicts prognosis in patients with laryngeal cancer. Hum Genomics，2019，13(1): 36.

NAUMANN R W， HOLLEBECQUE A， MEYER T， et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: Results from the phase I/II CheckMate 358 Trial. J Clin Oncol，2019，37(31): 2825–2834.

KWOK G， YAU T C， CHIU J W， et al. Pembrolizumab (Keytruda). Hum Vaccin Immunother，2016，12(11): 2777–2789.

KIM H D， SONG G W， PARK S， et al. Association between expression level of PD1 by tumor-infiltrating CD8+ T cells and features of hepatocellular carcinoma. Gastroenterology，2018，155(6): 1936–1950.e17.


Refbacks

  • There are currently no refbacks.